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Abstract
Background
The available clinical outcome measures of disability in multiple sclerosis are not ade-
quately responsive or sensitive.
Objective
To investigate the feasibility of inertial sensor-based gait analysis in multiple sclerosis.
Methods
A cross-sectional study of 80 multiple sclerosis patients and 50 healthy controls was per-
formed. Lower-limb kinematics was evaluated by using a commercially available magnetic
inertial measurement unit system. Mean and standard deviation of range of motion (mROM,
sROM) for each joint of lower limbs were calculated in one minute walking test. A motor per-
formance index (E) defined as the sum of sROMs was proposed.
Results
We established two novel observer-independent measures of disability. Hip mROM was
extremely sensitive in measuring lower limb motor impairment, being correlated with muscle
strength and also altered in patients without clinically detectable disability. On the other
hand, E index discriminated patients according to disability, being altered only in patients
with moderate and severe disability, regardless of walking speed. It was strongly correlated
with fatigue and patient-perceived health status.
Conclusions
Inertial sensor-based gait analysis is feasible and can detect clinical and subclinical disabil-
ity in multiple sclerosis.
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Introduction
Disability assessment had become fundamental part of standard multiple sclerosis (MS) prac-
tice and clinical research. Selecting an appropriate outcome measure for clinical trials is impor-
tant in determining whether the intervention is actually modifying the disease course,
especially because in MS the concept of relapse-free disease has been shifting into disease-free
status, thus requiring more sensitive metrics to determine efficacy. Moreover outcome mea-
sures and surrogate endpoints have been applied to the individual patient to evaluate disease
progression and the need for a change in therapy.
While disability may be considered an ideal primary endpoint in clinical research and a
therapeutic target in clinical practice, it can be difficult to both define and measure. The avail-
able clinical measures of disability in MS, including the expanded disability status scale (EDSS)
[1] and the MS Functional Composite (MSFC) [2] are not responsive and sensitive [3],[4].
Inter-rater variation has been reported to be greater than a 1-point increase in the EDSS about
40% of the time and difficulty in quantifying a meaningful change in the MSFC components
has been claimed [3]. An additional challenge for determining clinical meaningfulness is the
dichotomy between the patient's and the clinician's perceptions of change and the significant
impact of fatigue in the limitation of performance. Among MS patients, fatigue is the most
commonly reported symptom and one of the most debilitating, with significant socioeconomic
consequences [5], but it is often under-emphasized because of its complexity and subjective
nature. The International Advisory Committee on Clinical Trials in MS has recently pointed
out the need for novel collaborative approach to most effectively measure disability, including
the use of composite endpoints and patient-reported outcomes [4].
In literature, several studies were focused on the assessment of motor disabilities in patients
with MS by means of stereophotogrammetric systems [6–8]. However, these systems require
closed and restrained laboratories, they are expensive in terms of time and finance and they are
not useful in studies involving a large group of subjects [9]. In order to overcome the reported
drawbacks, Magnetic Inertial Measurement Units (MIMU/IMU) can be used instead of stereo-
photogrammetric systems. In fact, they can be utilized in wider and outdoor workspaces, they
do not require long lasting procedures for their use, and they are low cost devices [10]. In a
recent review on the use of MIMUs to objectively quantify motor disabilities of subjects with
neurological diseases, only one study was focused on subjects with MS [11]. In particular, the
authors found differences between subjects with MS and controls during gait, analyzing only
the range of motions of trunk angles. To the best of our knowledge, no studies have been con-
ducted in order to provide objective outcome measure for the evaluation of lower limb motor
disabilities in subjects with MS by means of MIMUs.
Aim of this study was to investigate the feasibility of gait analysis in MS, by using commer-
cial wearable inertial sensors, and to establish novel and sensitive observer-independent mea-
sures of disability.
Methods
This study complied with the principles of the Declaration of Helsinki, and was approved by
the Ethical Committee of the Policlinico Università Tor Vergata in Rome. All the subjects gave
their written informed consent to the study.
Subjects and Study Procedures
A total of 130 subjects was included in this study. Eighty patients with a diagnosis of MS [12],
were recruited by the MS Center of the Tor Vergata University Hospital of Rome. Fifty-six had
relapsing-remitting MS (RRMS), and 24 a secondary progressive MS (SPMS) [13]. Patients
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could not be enrolled if they relapsed in the 60 days preceding inclusion. Patients with
EDSS>6.5 or unable to complete the walking trial without aid were excluded. Other exclusion
criteria were: the need for an orthosis for stance control of the foot, ankle, and/or knee, the
receipt of botulinum toxin injections in the lower extremity within the preceding 6 months, the
use of a baclofen pump with unstable dosing in the last 3 months, a diagnosis of peripheral
nerve injury in the involved lower extremity with symptoms that limited participation in study
activities, or receipt of dalfampridine for the treatment of MS symptoms. Fifty age and sex-
matched subjects without neurological or other relevant medical conditions served as a refer-
ence population. Demographic and clinical details were derived from medical records and
shown in Table 1.
MS disease onset was defined as the first episode of focal neurological dysfunction indicative
of MS. Disease duration was estimated as the number of years from onset to the inclusion.
Patients underwent examination comprehensive of clinical assessment of disability, gait
analysis, questionnaires within 24 hours with at least 1 hour between the assessments. Healthy
controls (HC) only underwent gait analysis. Gait analysis was performed twice, a day apart, to
assess retest reliability.
Clinical Disability Assessment
Disability was determined by a specially trained and certified examining neurologist using
Expanded Disability Status Scale (EDSS) [1]. The timed 25 Foot Walk (T25FW), which mea-
sures the time a patient requires to cover a distance of 25 feet at maximum speed, was also
recorded. Clinical assessment of fatigue was performed by the same examining neurologist,
unaware of kinematic results, to cathegorize patients into two groups (patients with fatigue ver-
sus patients without fatigue) to assess the ability of gait analysis to discriminate patients with
fatigue respect to questionnaire score. Motor fatigue was assumed if the patient reported an
abnormal rapid physical exhaustion in daily living and if a severe reduction in maximum gait
distance could not be explained by the degree of paresis, spasticity or ataxia [14].
Gait Analysis
Participants were instructed to walk at a comfortable and self-selected speed along a leveled
walkway of 15 m for one minute. We defined the start and the end of the gait path with two
turn lines where the subjects reversed their walking direction by 180°. Walking trial was
repeated three times and the mean of kinematic variables along the trials were analyzed. Subject
that experienced fatigue at the end of each walking trial were allowed to rest on a chair until
they felt ready to perform the next repetition. Subjects were equipped with seven wireless
MIMUs (Xsens MTw, Xsens Technologies, Enschede, The Netherlands) placed on pelvis and
Table 1. Demographic and Clinical Characteristics of Subjects.
Total HC MS RRMS SPMS
Number 130 50 80 56 24
Age (years) 33.9±10.4 33.0±10.7 34.5±10.3 30.0±8.2 45.1±6.0
Sex (M/F) 53/77 20/30 33/47 21/35 12/12
Disease duration (years) - - 8.1±6.6 4.9±2.9 15.7±6.6
EDSS - - 3.3±1.6 2.5±1.3 5.1±0.8
M: male; F: Female; HC: Healthy Control; MS: Multiple Sclerosis; RRMS: Relapsing Remitting Multiple Sclerosis; SPMS: Secondary Progressive Multiple
Scleorosis; EDSS: Expanded Disability Status Scale.
doi:10.1371/journal.pone.0148997.t001
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on thigh, shank and foot of both legs (Fig 1). The effects of magnetic field distortions on
MIMU outputs were neglected moving any movable ferromagnetic materials out from the
experiment area [15]. The relative orientations of each MIMU and the related body segment
have been evaluated by means of a validated functional calibration procedure [16]. Specifically,
it consisted in the gathering of the sensor outputs for five seconds while the subject was keeping
still in two different positions: a standing upright posture and a sitting position with the trunk
backwards inclined and the legs stretched.
Data processing and data analysis were performed using MATLAB software (MathWorks,
USA). The acquired data fromMIMUs were post-processed in order to assess the angles of hip,
knee and ankle for both legs. Trials were then partitioned in gait cycles. Data related to turning
phases and to two strides after and before each turn were excluded from the evaluation, because
the lower limb kinematics could be altered by the turning event. Angle curves related to each
stride were resampled and normalized at 100 samples. Range of motion (ROM) of joint angle
curves on the sagittal plane was computed for each stride.
For each gait trial and each leg, means and standard deviations of ROM of hip (mROMH,
sROMH), knee (mROMK, sROMK) and ankle (mROMA, sROMA) were evaluated. As index of
the overall gait variability, the E index was calculated as sum of all sROMs related to each joint
of both legs. Higher is E value and higher is the variability of gait.
To estimate the asymmetry of kinematics of each i-th joint, we evaluated the symmetry indi-
ces SIH, SIK and SIA defined as [17]:
SIi ¼
jmROMiR mROMiLj
1
2
ðmROMiR þmROMiLÞ
 100
Where right and left limb have been addressed as R and L, respectively. Finally, in order to
evaluate the overall gait asymmetry we also calculated:
SI ¼ SIH þ SIK þ SIA
The SI value represents the magnitude of asymmetry between legs during the gait. The SI value
ranges from 0 to 600% and higher values represent a greater difference between the two sides.
Fig 1. Position of each MIMU on one subject.
doi:10.1371/journal.pone.0148997.g001
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The parameters mROMH, mROMK, mROMA, SI and E were addressed as kinematic
variables.
Questionnaires
Fatigue, quality of life and patient-perceived gait impairment were assessed by validated
questionnaires.
Fatigue was assessed by the Modified Fatigue Impact Scale (MFIS) [18] and the Fatigue
Severity Scale (FSS) [19] with higher scores indicating grater impact of fatigue on patient func-
tions and daily life. The Patient Reported Indices for MS (PRIMUS) consists of three indepen-
dent scales; symptoms, activity limitations and QoL designed to be used as standalone
measures or in combination. For the present study data were available for the QoL and activity
limitation scales. Both scales have been shown to be unidimensional and to have good repro-
ducibility and validity [20].
The impact of MS on the participants' perceived walking ability was assessed using the
12-item Multiple Sclerosis Walking Scale (MSWS-12) [21]. The MSWS-12 provides a score
with larger values indicating a greater perception of walking difficulty.
Statistical Analysis
Test-retest reliability was analyzed using intra-class correlation coefficients (ICC) with an ICC
(2,3) model. The between session reliability was analyzed using the mean parameters calculated
for the three walking trials for each session. The reliability was classified as excellent
(ICC 0.90), very good (ICC 0.80), good (ICC 0.70), moderate (ICC 0.6) or poor oth-
erwise. Continuous variables are summarized as mean ± standard deviation (SD). Categorical
variables are expressed as percentages. To determine differences between two groups, Student's
t-test or Mann-Whitney U test was used for continuous variables and the Fisher Exact test was
used for categorical variables. Analysis of variance (ANOVA) model was used to compare
across groups with different EDSS values. Univariable associations between kinematic variables
and clinical disability scales were investigated using Pearson’s correlation analysis or Spear-
man’s Rho analysis, as appropriate. Kinematic variables with significant association in univari-
able analysis were used to construct multivariable models, thus including also other
measurements of disability and possible confounding factors as age, gender, disease duration,
disease course. A ROC curve analysis and the area under the curve (AUC) were used to assess
the discriminating ability of the model. An area of 100% represents a perfect discrimination,
while an area of 50% represents a worthless model.
A p<0.05 was deemed significant. All tests should be understood as exploratory data analy-
sis as no prior power calculation and subsequent corrections for multiple testing were applied.
Results
Reproducibility of Lower Limb Kinematics
Gait analysis was performed twice, a day apart, to assess the retest reliability. Lower limb kine-
matics showed excellent retest reliability in HC and MS, as reported in Table 2.
Analysis of Lower Limb Kinematics in MS Patients
Five gait parameters were derived from the lower limb kinematics analysis and compared
between HC and MS patients. Reduced mROMH, mROMK, and mROMA, were found in MS
group with respect to HC group (p<0.05 for each comparisons; Fig 2A). MS patients presented
also a significantly higher variability of gait, as documented by E index (p<0.05; Fig 2B).
Objective Measures of Disability in Multiple Sclerosis
PLOS ONE | DOI:10.1371/journal.pone.0148997 February 10, 2016 5 / 12
Conversely, SI was not significantly different between the two groups, although higher among
MS subjects (p>0.05; Fig 2C).
We then included all the gait parameters significantly different between the HC and MS
group in a multivariable model with group as dependent variable, and demographics as possi-
ble confounding factors. Two parameters, mROMH and E were found to be independently able
to discriminate the MS from the HC group (Table 3). The discriminating ability of mROMH
was higher, as assessed by the ROC analysis (mROMH: AUC = 93.8%, 95%CI = 89.2–98.5%,
Fig 2D; E: AUC = 79.2%, 95%CI = 71.0–87.3%).
Finally, gait parameters were compared between RRMS and SPMS patients. Gait variability
was significantly higher in progressive patients (E: 18.9±5.0° versus 13.4±3.8°; p<0.05),
whereas mROMs were significantly lower (mROMH: 31.0±3.0° versus 36.6±6.3°; mROMK:
44.4±6.9° versus 54.9±6.0°; mROMA: 27.2±7.0° versus 35.4±7.4°; p<0.05). No difference was
revealed in SI analysis (RRMS: 27.1±16.5%, SPMS: 29.4±11.0%; p>0.05). All kinematic param-
eters significantly different between RRMS and SPMS group were included in a multivariable
model with groups as dependent variable, and demographics as possible confounding factors.
E was the only independent variable associated to progressive disease in our sample, as showed
in Table 3, with a high discriminating ability assessed by the ROC analysis, even higher than
the standardized measure of motor impairment (E AUC = 0.81, 95%CI = 0.68–0.93, Fig 2E;
T25FW AUC = 0.74, 95%CI = 0.61–0.87).
Correlation between Hip mROM and Disability
The correlations of mROMH with clinical variables are shown in Table 4. In particular,
mROMH significantly correlated with pyramidal subscore and with T25FW (p<0.05; Fig 3A),
as a measure of lower limb motor impairment. Multivariable models confirmed the association
between mROMH and EDSS, including demographics and clinical characteristics as possible
confounding factors (Coef = -0.08, 95%CI -0.01–0.04, p<0.01) but failed to confirm signifi-
cantly association at equal value of pyramidal score and T25FW (Coef = 0.01; p>0.1), indicat-
ing mROMH as index of motor impairment rather than an index of overall disability.
Further, significant correlation was found between mROMH and patient-perceived gait
impairment assessed by the MSWS questionnaire (p<0.05; Fig 3B). In line with previous data
showing high sensitivity in detecting MS status, we analyzed mROMH among subjects dichoto-
mized as asymptomatic (EDSS 0–1.5) or symptomatic (EDSS>1.5). Interestingly, mROMH
was significantly altered also in MS subjects without clinical disability (p<0.05; Fig 3C).
Correlation between E Index and Disability
We then analyzed gait variability according to different levels of disability. An increased of E
was found with increasing disability, passing from asymptomatic patients, to patients with
Table 2. Intra-class Correlation Coefficients of Lower Limb Kinematics.
Kinematics HC MS
mROMH 0.983 0.976
mROMK 0.985 0.997
mROMA 0.995 0.997
SI 0.969 0.984
E 0.825 0.877
HC: Healthy Control; MS: Multiple Sclerosis; mROM: mean Range Of Motion; SI: Symmetry Index.
doi:10.1371/journal.pone.0148997.t002
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Fig 2. Lower limb kinematics alterations in MS patients. Lower limb kinematics alterations in MS patients. (A) The graph shows thatmROMwas
significantly lower in MS group respect to HC group in each joint. (B) MS patients presented significantly higher variability of gait, as documented by E
analysis. (C) SI was not significantly different between MS and HC group. (D), (E) Area under the ROC curves measured the accuracy of mROMH in
discriminating HC fromMS (D) and the accuracy of E index in discriminating RRMS from SPMS (E). *means p<0.05.
doi:10.1371/journal.pone.0148997.g002
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EDSS = 2.0–4.0 and patients with EDSS>4.0 (p<0.05; Fig 4A). Of note, no difference was evi-
dent between HC and asymptomatic MS patients (p>0.05). A multivariable model confirmed
the association between E and EDSS, at equal value of disease duration, age, sex, disease course
(Coef = 0.074, 95%CI = 0.01–0.13, p = 0.017), indicating a correlation with disability also in
RRMS patients.
E index significantly correlated with EDSS and pyramidal score, but not with T25FW, as
shown in Table 4. A multivariable model confirmed the association between E and EDSS, at
equal value of pyramidal score (Coef = 0.064, 95%CI = 0.03–0.09, p = 0.02), proposing E as
index of overall disability, also regardless motor impairment.
Furthermore, significant correlations were found with fatigue assessed by both FSS and
MFIS (p<0.05, Fig 4A and 4C). A multivariable model confirmed the association between E
and the clinical assessment of fatigue (OR = 1.59, SE:0.19, p<0.0001, 95%CI = 1.27–2.02),
including demographics and clinical variable (EDSS and pyramidal subscore) as possible con-
founding factors. The ability to discriminate patients with fatigue was revealed by ROC analysis
and it was even higher respect to questionnaire scores (AUCE = 0.91, 95%CIE = 0.84–0.97;
AUCFSS = 0.79, 95%CIFSS = 0.68–0.90; AUCMFIS = 0.81, 95%CIMFIS = 0.70–0.91; Fig 4D).
Finally, E correlated with quality of life, activity limitation and perceived walking ability (Table 4).
Discussion
New measures to detect disability and its progression are claimed in MS for both clinical prac-
tice and trial design. In this cross-sectional study we investigated the applicability and feasibil-
ity of inertial sensor-based gait analysis in MS.
We first found that in both MS and HC subjects there was an excellent repeatability of most
of the motor performance parameters evaluated in a single session. Then, a multivariable
model revealed that two kinematic variables (E and mROMH) were able to independently dis-
tinguish MS from control group. The mROMH measured motor impairment, being signifi-
cantly correlated with walking speed and pyramidal functional score, whereas E was likely to
assess overall disability, being correlated to EDSS even regardless motor strength. In line with
Table 3. Multivariable Models: Association Between Kinematic Parameters and MS Disease.
MS/HC OR SE p CI
Age 0.94 0.03 0.09 0.89–1.01
Sex 2.14 1.5 0.28 0.54–8.52
mROMA 0.92 0.04 0.07 0.83–1.01
mROMK 0.97 0.03 0.53 0.91–1.05
mROMH 0.75 0.05 <0.0001 0.65–0.87
E 1.17 0.09 0.038 1.01–1.37
SPMS/RRMS
Age 1.49 2.10 0.005 1.12–1.98
Sex 0.93 1.26 0.96 0.06–13.27
mROMA 0.84 0.09 0.11 0.67–1.04
mROMK 0.85 0.09 0.12 0.69–1.04
mROMH 0.79 0.17 0.27 0.52–1.20
E 1.43 0.22 0.02 1.06–1.93
MS: Multiple Sclerosis; HC: Healthy Control; SPMS: Secondary Progressive Multiple Scleorosis; RRMS:
Relapsing Remitting Multiple Sclerosis; OR: odds ratio; SE: standard error; CI: confidence interval; mROM:
mean Range Of Motion.
doi:10.1371/journal.pone.0148997.t003
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this, E correlated very well with both clinically assessed and self-reported physical fatigue. Pres-
ently, there is no ‘‘gold standard” for detecting motor fatigue. Commonly, fatigue is assessed by
several questionnaires including the FSS [19] and MFIS [18], based on patients’ self-assess-
ments of the general condition. Hence, an objective tool for assessing motor fatigue in MS is
crucial for a more precise diagnosis and for the design of treatment and rehabilitation pro-
grams. Recently, measurement of fatigue in term of decline in walking speed or change in gait
pattern, have been proposed [14],[22]. Here, we have introduced a numerical index to objec-
tively assess gait variability. E correctly classified patients with MS into fatigue and non-fatigue
groups, better than validated questionnaires and even before the appearance of motor fatigue.
Furthermore, E index was able to discriminate progressive disease, indicating a new tool for
monitoring disability among RRMS subjects. To date, no reliable markers of progressive dis-
ease course are available. Longitudinal studies will be useful to assess E changes during RR-SP
transition phase and verify their prognostic value. On the other hand, mROMH was also able to
distinguish HC fromMS patients with very low EDSS scores: a significant difference was
Table 4. Lower Limb Kinematics Correlation with Clinical and Patient-reported Outcomes.
Questionnaire/Scale mROMH E
r p r p
FSS -0.13 0.23 0.60 <0.001
MFIS -0.11 0.30 0.63 <0.001
MFISphysical -0.07 0.55 0.67 <0.001
MFIScognitive -0.12 0.28 0.48 <0.001
MFISpsycosocial -0.14 0.21 0.63 <0.001
MSWS -0.62 <0.001 0.46 <0.001
PRIMUSQoL -0.17 0.12 0.72 <0.001
PRIMUSActivityLimitation -0.11 0.33 0.63 <0.001
EDSS -0.59 <0.001 0.58 <0.001
Pyramidal subscore -0.61 <0.001 0.57 <0.001
T25FW -0.51 <0.001 0.10 0.36
mROMH: mean range of motion of hip; FSS: Fatigue Severity Scale; MFIS: Modified Fatigue Impact Scale; MSWS: Multiple Sclerosis Walking Scale;
PRIMUS: Patient Reported Indices for Multiple Sclerosis; EDSS: Expanded Disability Status Scale; T25FW: Timed 25 Foot Walk.
doi:10.1371/journal.pone.0148997.t004
Fig 3. mROMH detects subclinical motor disability. (A) mROMH significantly correlated with T25FW. (B) Significant correlation was found between
mROMH and patient-perceived gait impairment assessed by the MSWS questionnaire. (C) mROMH was significantly altered in MS subjects with clinical
disability (EDSS>1.5) and without clinical disability (EDSS1.5) compared to HC subjects. *means p<0.05.
doi:10.1371/journal.pone.0148997.g003
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already evident for patients with EDSS<2.0, demonstrating a high sensitivity in detecting a
subclinical impairment. Further longitudinal studies will be useful to investigate the sensitivity
of the mROMH in early detecting disability progression.
In conclusion, we established two novel observer-independent measures of disability. E dis-
criminated MS patients according to disability, whereas mROMH was extremely sensitive in
measuring motor impairment within patients. If confirmed in larger studies, this sensitivity
will be of crucial importance for monitoring disease course and treatment effects in RRMS
patients, when changes in the EDSS are small or absent, and in progressive MS patients, when
also small and slow changes in the EDSS are the primary outcomes to assess.
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